Overview of ecallantide in the treatment of hereditary angioedema types I and II

ISSN： 1475-0708

Source： Therapy, Vol.7, Iss.5, 2010-09, pp. : 565-571

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency

By Bernstein Jonathan A Biedenkapp Joseph

Clinical Investigation, Vol. 3, Iss. 9, 2013-09 ,pp. : 859-873

Future Science

Access to resources Recommend Favorite

Recent Advances in Hereditary Angioedema Self-Administration Treatment: Summary of an International Hereditary Angioedema Expert Meeting

International Archives of Allergy and Immunology, Vol. 161, Iss. 1, 2013-05 ,pp. : 1-2

Karger

Access to resources Recommend Favorite

Recent Advances in Hereditary Angioedema Self-Administration Treatment: Summary of an International Hereditary Angioedema Expert Meeting

International Archives of Allergy and Immunology, Vol. 161, Iss. 1, 2013-05 ,pp. : 26-27

Karger

Access to resources Recommend Favorite

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

ALLERGY, Vol. 105-4538, Iss. 10, 2015-10 ,pp. : 1319-1328

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

ALLERGY, Vol. 70, Iss. 10, 2015-10 ,pp. : 1319-1328

John Wiley & Sons Inc

Access to resources Recommend Favorite